All In MedTech

Device Trial Radar · NCT01307501

Safety and Efficacy of Cryoablation for Metastatic Lung Tumors

Evaluating Cryoablation of Metastatic Lung/Pleura Tumors in Patients - Safety and Efficacy

Last checked: Nov 19, 2026Latest source record: Jul 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Jan 4, 2012

Primary completion

Aug 30, 2018

Study completion Aug 30, 2018

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Mar 3, 2011

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ECLIPSE will evaluate the safety and efficacy of cryoablation therapy used to treat tumors less than or equal to 3.5 centimeters (cm) in participants with pulmonary metastatic disease.

Conditions

  • Metastatic Lung Cancer

Interventions

  • CryoablationDevice

    Application of extremely cold temperatures to the identified tumor(s).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Local Tumor Control for Each Index Tumor as Measured by Imaging at Month 60Time frame: Baseline and Month 60

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Ronald Regan UCLA Medical Center

    Los Angeles, California

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.